Is Semaglutide Injection Safe to Use for Weight Loss?

Semaglutide injection (Wegovy) is a weight management drug that has attracted much attention around the world in recent years. It was originally developed by Novo Nordisk for blood sugar control in type 2 diabetes. However, it was subsequently found to have significant weight loss effects and was approved by the US FDA for long-term weight management. The main ingredient of Wegovy is Semaglutide, which is a GLP-1 receptor agonist (glucagon-like peptide-1 analog). By simulating the GLP-1 hormone in the human body, it delays gastric emptying, reduces appetite, and enhances satiety, thereby reducing food intake and promoting energy metabolism. Because its mechanism is close to the physiological regulation of the human body, rather than weight loss through forced suppression or dehydration, it is regarded as a relatively mild and long-lasting method of weight loss.

From a security perspective, it is generally believed thatWegovy has high security. It has been shown in multiple clinical studies in Europe and the United States that users can reduce their average weight by 10% to 15% over a period of more than one year, and most subjects tolerate it well. Unlike traditional central nervous system drugs that suppress appetite, semaglutide does not act directly on the nervous system and does not cause dependence or cardiovascular excitability problems. However, the drug is a hormone regulator after all and may still produce certain adverse reactions, such as nausea, vomiting, mild abdominal distension, decreased appetite, constipation, etc. These are usually noticeable early in treatment and lessen as the body adapts.

A small number of users may experience pancreatitis or gallbladder-related symptoms, such as persistent abdominal pain or jaundice, which is related to the mechanism of GLP-1 agonists. Patients with a history of pancreatic disease, gallstones, or severe gastrointestinal disease should use it with caution under the guidance of a physician. In addition, the use of semaglutide is not recommended for pregnant and lactating women because there is currently insufficient safety research data.

Reference materials:https://www.drugs.com